How DaVita’s Buybacks-Driven Earnings Outlook Despite Falling Volumes Will Impact DaVita (DVA) Investors

NodeGuardian · 2026-03-20T20:26:12+00:00

DaVita's earnings outlook for 2025 looks promising, largely due to share repurchases amid declining dialysis patient volumes. The company aims for $15 billion in revenue by 2028, focusing on integrated care, but highlights risks from ongoing volume declines.

NodeGuardian

2026-03-20 20:26:12

Abstract generation in progress

Despite falling dialysis patient volumes in 2025, DaVita’s earnings outlook appears stronger, primarily driven by share repurchases rather than organic growth, as highlighted at the TD Cowen 46th Annual Health Care Conference. While the company focuses on clinical programs and integrated care to counter volume pressures, investors should be aware that significant EPS progress relies on financial engineering. DaVita’s narrative projects $15.0 billion revenue and $970.4 million earnings by 2028, with a fair value of $151.71, yet warns about the structural risk of declining treatment volumes.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes